82 fold, p=0.04) and citrulline (0.75 fold, p=0.03) were decreased in NASH vs. NAFL subjects. (5) Glycine, serine and threonine pathway: Betaine was decreased (0.80 fold, p=0.048 NASH vs. control and p=0.03 NASH vs. NAFL) in NASH subjects. (6) Lysine (0.84 fold, p=0.01) and methionine (0.85 fold, p=0.018) concentrations related to lysine and cysteine, methionine, S-adenosyl methionine (SAM), and taurine pathways, were significantly Talazoparib nmr low in NASH subjects vs. NAFL. Pathway enrichment and pathway impact analysis: While the most enriched pathway in NASH was lysine

degradation (>6-folds) with 3-4-folds enrichment in betaine, aspartate and methionine metabolism, the most pathway impact was by arginine and proline, and glycine, serine and threonine pathways. CONCLUSION: Plasma amino acid metabolome highlights several amino acids and its metabolite abnormalities in NAFLD. Lysine degradation pathway is highly enriched and arginine and proline pathway has most impact in NASH. Disclosures: Puneet Puri – Advisory Committees or Review Panels: Health Diagnostic Laboratory Inc.; Consulting: NPS Pharmaceuticals Inc. Andrew R. Joyce – Independent Contractor:

Venebio selleck chemicals llc Group, LLC; Management Position: Venebio Group, LLC Arun J. Sanyal – Advisory Committees or Review Panels: Bristol Myers, Gilead, Abbott, Ikaria; Consulting: Salix, Immuron, Exhalenz, Nimbus, Genentech, Echo-sens, Takeda; Grant/Research Support: Salix, Genentech, Genfit, Intercept, Ikaria, Takeda, GalMed, Novartis, Gilead; Independent Contractor: UpToDate, Elsevier The following people have nothing to disclose: Velimir A. Luketic, Mohammad S. Siddiqui, Sherry L. Boyett, Jolene Schlosser, Carol Sargeant, Kalyani Daita, Hae-Ki Min, Faridoddin Mirshahi Background and aim: Nonalcoholic fatty liver disease (NAFLD) and its progressive form, nonalcoholic steatohepatitis

acetylcholine (NASH), are rapidly being a worldwide health concern. Epidemiological studies have shown that the prevalence of NAFLD is higher in men than women. This gender difference disappears after menopause. Estrogen therapy has been shown to be protective against NAFLD/NASH after menopause. Whereas the administration of exogenous estrogens resulted in some potential risks, such as uterus cancer, limiting their clinical use. However, selective estrogen receptor modulator (SERM), acts in distinct ways and exert tissue-specific responses by interacting with estrogen receptors. Raloxifene, a second-generation of SERM which has been used for treatment of breast cancer and postmenopausal osteoporosis, has been shown to decrease serum cholesterol, low-density lipoprotein cholesterol. Here, we aimed to investigate the therapeutic effect of ralxofiene on NASH induced by choline deficient and high fat (CDHF) diet in ovariectomized (OVX) mice, a model of menopause.